Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons with Opioid Use Disorder: A Case Series
-
Register
- Non-Member - $39
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons with Opioid Use Disorder: A Case Series
Published: January/February 2024
Journal Article
Overview
This one-hour, on-demand, journal article-based activity reviews a brief report on the use of monthly subcutaneous injectable buprenorphine (XR-Bup) as an option for treatment of opioid use disorder. While infrequently offered to hospitalized patients with OUD at present, this treatment option should be considered as a way to initiate and support maintenance of on-going MOUD treatment after hospital discharge and to mitigate sublingual buprenorphine adherence barriers.
The target audience for this intermediate activity includes physicians, nurse practitioners, PAs, pharmacists, social workers, counselors, and other clinicians, researchers, students, and policymakers.
This activity addresses the following ACGME Core Competencies: Patient Care, Medical Knowledge, Interpersonal and Communication Skills, Practice-Based Learning and Improvement, Professionalism, and Systems-Based Practice.
Article Abstract
Objectives: Monthly subcutaneous injectable buprenorphine (XR-Bup) is an option for treatment of opioid use disorder that addresses some sublingual buprenorphine adherence barriers and is infrequently offered to hospitalized patients with OUD.
Methods: Retrospective case series of patients receiving XR-Bup upon discharge from one academic medical center. Demographic information, diagnoses, follow-up, and documented factors informing the selection of XR-Bup were extracted from the electronic health record.
Results: In one year, 37 hospitalized patients with OUD received XR-Bup at discharge. The average age was 37.6 years, and patients were primarily Medicaid-insured with an injection-related infection. The most common documented factors informing the selection of XR-Bup were: previous sublingual buprenorphine adherence barriers, concurrent stimulant use disorder, and patient preference. Sixty-four percent of patients scheduled for follow-up attended appointments, and 55% received a second dose of XR-Bup.
Conclusion: XR-Bup is an option for OUD treatment among hospitalized patients providing 30 or more days of buprenorphine coverage in the post-discharge period.
Learning Objectives
Upon completion, learners will be able to:
- Recognize the key factors informing the selection of extended-release buprenorphine for patients with OUD at discharge from hospital.
- Consider the option of initiating monthly subcutaneous injectable buprenorphine (XR-Bup) for hospitalized patients to address common sublingual buprenorphine adherence barriers and its potential to facilitate retention in MOUD during the high-risk post–hospital discharge transition period.
Registration Rates
Rate Description | Rate |
ASAM Member | $0 |
Non-Member | $39 |
Associate Member | $0 |
Resident Member* | $0 |
Student Member* | $0 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 02/5/2027
Close Access Date: 03/05/2027
Course Instructions
- Click on the Contents tab to begin this activity.
- Click View Journal Article and read the journal article in its entirety.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer Essential Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Accreditation & Credit Designation Statements
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This activity awards 1 Nursing contact hours.
Pharmacy
This activity will offer 1 pharmacy contact hours (1 CEUs). Pharmacists will be asked to provide identifying information (e-Profile ID and DOB in MMDD format) in order to receive credit and allow reporting to CPE Monitor. (UAN: JA0000141-0000-24-008-H01-P)